Frontlight ResearchEarly access
CompletedNo phase
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
Key facts
- Who runs it
- Beijing Tiantan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 228 people enrolled
- Started
- 30 Oct 2020
- Ended
- 11 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tranexamic acid
- 0.9% saline
- Record updated
- 4 March 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 1) age 18-80 years
- 2) American Society of Anesthesiologist (ASA) classification score I~III
Who cannot take part
- 1) allergic to tranexamic acid
- 2) preoperative seizures
- 3) history of thrombotic disease
- 4) chronic kidney disease
- 5) breastfeeding or pregnancy
- 6) refuse to participate in the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Growing evidence of Tranexamic Acid (TXA) being used to reduce blood loss and blood transfusions in various guidelines. However, the adverse effects of TXA especially seizure has always been a problem of concern, especially in neurosurgery. Therefore, this study aims to provide a scientific evidence for the safety of TXA in supratentorial meningiomas resection patients.
The 2 groups in the trial
- TXA groupExisting treatment, for comparison
The TXA group will receives Tranexamic acid intraoperative.
Treatment: Tranexamic acid
- Placebo groupPlacebo, for comparison
The TXA group will receives 0.9% saline intraoperative.
Treatment: 0.9% saline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized, Parallel-group, Placebo Control, Non-inferiority Trial to Investigate the Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
- Record updated
- 4 March 2025